Invitae Corporation (NYSE:NVTA) shares are trading lower this Wednesday after the company reported fourth-quarter financial results and provided guidance for full-year 2023. The company also announced ...

Outcomes4Me Inc., developer of a leading free mobile app and platform to navigate cancer treatment and care, has partnered with Invitae Corp., a leading medical genetics company, to expand education ...

This week, Invitae put out a press release highlighting the insights Praxis Precision Medicines was getting from Invitae's Citizen platform. The platform enables companies to get medical history data ...

SEATTLE, July 22, 2021 /PRNewswire/ — Volpara Health, a global health technology software leader providing an integrated breast care platform for the delivery of personalized breast care, has signed ...

After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which ...

In this article we will take a look at whether hedge funds think InVitae Corporation (NYSE:NVTA) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving ...

Invitae Corporation (NYSE: NVTA), which specializes in medical genetic testing, saw its shares climb as high as 23% this week, according to data from S&P Global Intelligence. The stock closed at $2.30 ...

A little more than two years after California genetics-testing company Invitae Corp. (NYSE: NVTA) bought ArcherDX Inc., a Boulder developer of genetic assays for cancer patients, for $1.4 billion, ...

Hi, everyone. Good afternoon. Thanks for joining us here. If you don't know me, my name is Andrew Brackmann, I cover diagnostics for William Blair. This afternoon, we have Invitae joining us. We have ...

Yes. Thank you. Great. We are just about at the time here 1:30. So sorry about that. Welcome. Obviously, day one of the TD Cowen Health Care Conference. I am Dan Brennan. One of the tools analyst here ...